Progress and Current Status in Hajdu-Cheney Syndrome with Focus on Novel Genetic Research

Int J Mol Sci. 2022 Sep 27;23(19):11374. doi: 10.3390/ijms231911374.

Abstract

Hajdu-Cheney syndrome (HCS) is a rare autosomal dominant manifestation of a congenital genetic disorder caused by a mutation in the NOTCH2 gene. NOTCH signaling has variations from NOTCH 1 to 4 and maintains homeostasis by determining and regulating the proliferation and differentiation of various cells. In HCS, the over-accumulated NOTCH2 causes abnormal bone resorption due to its continuous excessive signaling. HCS is characterized by progressive bone destruction, has complex wide-range clinical manifestations, and significantly impacts the patient's quality of life. However, no effective treatment has been established for HCS to date. There are genetic variants of NOTCH2 that have been reported in the ClinVar database of the U.S. National Institutes of Health. In total, 26 mutant variants were detected based on the American College of Medical Genetics and Genomics (ACMC). To date, there has been no comprehensive compilation of HCS mutations. In this review, we provide the most comprehensive list possible of HCS variants, nucleotide changes, amino acid definitions, and molecular consequences reported to date, following the ACMC guidelines.

Keywords: Hajdu-Cheney syndrome; NOTCH2; bone disease; genes in bone tissues; osteoporosis.

Publication types

  • Review

MeSH terms

  • Amino Acids / genetics
  • Genetic Research
  • Hajdu-Cheney Syndrome* / genetics
  • Hajdu-Cheney Syndrome* / metabolism
  • Humans
  • Mutation
  • Nucleotides
  • Quality of Life

Substances

  • Amino Acids
  • Nucleotides